In the past week, IMRX stock has gone up by 9.33%, with a monthly decline of -4.95% and a quarterly surge of 104.85%. The volatility ratio for the week is 7.36%, and the volatility levels for the last 30 days are 7.03% for Immuneering Corp The simple moving average for the past 20 days is 6.00% for IMRX’s stock, with a -11.24% simple moving average for the past 200 days.
Is It Worth Investing in Immuneering Corp (NASDAQ: IMRX) Right Now?
IMRX has 36-month beta value of -0.43. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for IMRX is 21.00M, and currently, short sellers hold a 9.74% ratio of that float. The average trading volume of IMRX on November 14, 2024 was 5.45M shares.
IMRX) stock’s latest price update
Immuneering Corp (NASDAQ: IMRX)’s stock price has increased by 23.39 compared to its previous closing price of 1.71. However, the company has seen a 9.33% increase in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-13 that – Announced Positive Initial Data, Including Complete and Partial Responses, with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients – – Granted FDA Orphan Drug Designation for IMM-1-104 in the Treatment of Pancreatic Cancer and Fast Track Designation in First-line Pancreatic Cancer – – Initial Data From At Least One Additional Arm of the Phase 2a Portion of the IMM-1-104 Phase 1/2a Trial Expected by Year End – – Cash Runway into Fourth Quarter 2025 – CAMBRIDGE, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today reported financial results for the third quarter ended September 30, 2024, and provided business updates.
Analysts’ Opinion of IMRX
Many brokerage firms have already submitted their reports for IMRX stocks, with Needham repeating the rating for IMRX by listing it as a “Buy.” The predicted price for IMRX in the upcoming period, according to Needham is $15 based on the research report published on March 15, 2024 of the current year 2024.
Jefferies gave a rating of “Hold” to IMRX, setting the target price at $3 in the report published on March 15th of the current year.
IMRX Trading at -2.12% from the 50-Day Moving Average
After a stumble in the market that brought IMRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -76.27% of loss for the given period.
Volatility was left at 7.03%, however, over the last 30 days, the volatility rate increased by 7.36%, as shares sank -2.64% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +71.00% upper at present.
During the last 5 trading sessions, IMRX rose by +5.44%, which changed the moving average for the period of 200-days by -65.33% in comparison to the 20-day moving average, which settled at $1.9867. In addition, Immuneering Corp saw -71.29% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMRX starting from Cormorant Asset Management, LP, who sale 400,000 shares at the price of $2.90 back on Apr 01 ’24. After this action, Cormorant Asset Management, LP now owns 2,895,273 shares of Immuneering Corp, valued at $1,160,181 using the latest closing price.
Schall Thomas J., the Director of Immuneering Corp, purchase 2,900 shares at $2.55 during a trade that took place back on Mar 22 ’24, which means that Schall Thomas J. is holding 2,900 shares at $7,385 based on the most recent closing price.
Stock Fundamentals for IMRX
Current profitability levels for the company are sitting at:
- 162.26 for the present operating margin
- 1.01 for the gross margin
The net margin for Immuneering Corp stands at 155.06. The total capital return value is set at -0.25. Equity return is now at value -61.81, with -55.52 for asset returns.
Based on Immuneering Corp (IMRX), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -9.55. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -14.25.
Currently, EBITDA for the company is -58.06 million with net debt to EBITDA at 2.67. When we switch over and look at the enterprise to sales, we see a ratio of 433.24. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.39.
Conclusion
To put it simply, Immuneering Corp (IMRX) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
